Agile Therapeutics Inc (AGRX.OQ)
15 Oct 2018
Agile Therapeutics Inc's shares sank 75 percent on Friday after the drug developer said it expects to pursue what could be a prolonged appeal against health regulators' issues over its chief experimental product, a contraceptive patch.
* FDA suggests additional study of contraceptive may be needed
May 18 Agile Therapeutics Inc said on Friday it was looking for ways to fund operations after a meeting with the U.S. health regulator raised the possibility of a new clinical trial to test its stick-on contraceptive patch, Twirla.
BRIEF-Agile Therapeutics Provides Regulatory Update On Twirla® (Ag200-15) For The Prevention Of Pregnancy
* AGILE THERAPEUTICS, INC. PROVIDES REGULATORY UPDATE ON TWIRLA® (AG200-15) FOR THE PREVENTION OF PREGNANCY
* AGILE THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS